identify product candidates targeting CSCs may not result in the discovery and development of commercially viable drugs to treat cancer.
The other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.6Table of ContentsThe offeringCommon stock offered by us4,500,000 sharesCommon stock to be outstanding after this offering19,234,116 sharesOver-allotment optionThe underwriters have an option for a period of 30 days to purchase up to 675,000 additional shares of our common stock to cover over-allotments.Use of proceedsWe intend to use the net proceeds from this offering for preclinical and clinical development of our lead product candidates, discovery, research and preclinical studies of our other product candidates,
expenses payable by us.As of September 30, 2011Balance sheet data:ActualPro formaPro formaas adjusted(in thousands)Cash and cash equivalents$41,421$61,824$101,574Working capital39,41959,82299,572Total assets42,36462,767102,517Redeemable convertible preferred stock47,878——Deficit accumulated during the development stage(8,462)(8,462)(8,462)Total stockholders' (deficit) equity(7,639)60,642100,39210Table of ContentsRisk factorsInvesting in our common stock involves a high degree of risk.
circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL CAPITALWe have incurred significant losses since our inception.
staffing our company, business planning, raising capital, acquiring and developing our technology, identifying potential product candidates and undertaking preclinical studies of our most advanced
large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.We expect that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at
Adequate additional financing may not be available to us on acceptable terms, or at all.Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish
development of commercially viable drugs to treat cancer.We may not be successful in our efforts to identify or discover additional potential product candidates.A key element of our strategy is to identify and test additional compounds that target CSCs in a variety of different types of cancer.
we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenues in future periods, which likely would result in significant
harm to our financial position and adversely impact our stock price.14Table of ContentsRisk factorsWe may not be successful in obtaining necessary rights to compounds and product candidates for our development pipeline through acquisitions and in-licenses.Because we are screening a range of compounds, including compounds with proprietary rights held by third parties, for their activity against CSCs,
to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.We have invested a significant portion of our efforts and financial resources in the identification and preclinical development of drugs that target
results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates,
clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.If serious adverse or inappropriate side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of
that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIESWe expect to depend on collaborations with third parties for the development and commercialization of our product candidates.
or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and
scope, progress, results and costs of compound discovery, preclinical development, laboratory testing and clinical trials for our product candidates;–>the
scope, progress, results and costs of compound discovery, preclinical development, laboratory testing and clinical trials for our product candidates;–>the